NEW YORK and SUZHOU, China, Sept. 4, 2025 /PRNewswire/ — Accro Bioscience (Accropeutics), a clinical-stage biotech company focused on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announced that it will present results from a Phase II clinical study evaluating AC-201, an oral, selective TYK2/JAK1 Inhibitor, in moderate-to-severe plaque psoriasis, at the European Academy of Dermatology & Venereology (EADV) Congress, being held September 17-20th, in Paris.
Details of the presentation are as follows:Abstract Type: Oral Presentation in the Late Breaking SessionsAbstract ID: LBA-5Abstract Title: Efficacy and Safety of a Selective Oral TYK2/JAK1 Inhibitor, AC-201, in Patients with Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled TrialSession Title: D3T01.4FSession Room: Paris NordPresentation Time: 17:15 – 17:30 Friday, 19 September
About AC-201
AC-201 is a novel, highly selective and potent oral small-molecule inhibitor of TYK2/JAK1 that binds to the pseudo kinase domain (JH2) of TYK2/JAK1, with minimal effect on the JAK2/JAK2 signaling pathway. It is currently being developed to treat immune mediated inflammatory diseases such as psoriasis (PsO), non-infectious uveitis (NIU), and cutaneous lupus erythematosus (CLE). Phase 1 studies in healthy volunteers conducted in Australia and China demonstrated that AC-201 was generally safe and well-tolerated across all dose groups, with no adverse events (AEs) leading to discontinuation or serious adverse events (SAEs).
About Accro Bioscience
Accro Bioscience is a clinical-stage biotech company with a core focus on the molecular mechanisms of regulated cell death and related pathogenesis in human diseases. The company currently has three clinical-stage assets. AC-201, a selective TYK2/JAK1 inhibitor with therapeutic potential across a broad range of immune mediated inflammatory diseases, has completed a Phase 2 clinical trial in psoriasis with positive efficacy and safety readout. The RIPK2 inhibitor, AC-101, has completed the Phase 1 study in Australia and China with excellent safety and PK/PD data, and a Ph1b trial in UC patients is currently ongoing. The RIPK1 inhibitor, AC-003, obtained Orphan Drug Designation from the FDA, has completed the Phase 1 study in China and the United States, and is currently in a Phase 1b trial for the treatment of aGvHD patients. Accro Bioscience owns global rights of the assets with 25 patents issued in China, Japan, US, Korea and EU.
Media Contact:Jack XuAccro BioscienceInfo@accropeutics.com
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
